TREATMENT OF ADVANCED GASTRIC-CANCER WITH THE COMBINATION FLUOROURACIL, LEUCOVORIN, ETOPOSIDE, AND CISPLATIN - A PHASE-II STUDY OF THE ONCOPAZ COOPERATIVE GROUP

被引:4
|
作者
GONZALEZBARON, M
FELIU, J
ESPINOSA, E
GARCIAGIRON, C
CHACON, I
GARRIDO, P
COLMENAREJO, A
ORDONEZ, A
ZAMORA, P
机构
[1] HOSP LA PAZ, MED ONCOL SERV, E-28046 MADRID, SPAIN
[2] HOSP GEN YAGUE, MED ONCOL SERV, E-09080 BURGOS, SPAIN
[3] HOSP VIRGEN SALUD, MED ONCOL SERV, TOLEDO, SPAIN
[4] HOSP RAMONG CAJAL, MED ONCOL SERV, MADRID, SPAIN
[5] HOSP MIL AIRE, MED ONCOL SERV, MADRID, SPAIN
关键词
GASTRIC CANCER; CHEMOTHERAPY; TOXICITY;
D O I
10.1007/BF00685856
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A phase II study was performed to assess the efficacy and toxicity of the combination of 5-fluorouracil (5-FU), leucovorin (LV), etoposide, and cisplatin (FLEP) in patients with advanced gastric carcinoma. A total of 46 consecutive, previously untreated patients with unresectable, measurable gastric carcinoma were treated with 300 mg/m(2) LV, 100 mg/m(2) etoposide, 500 mg/m(2) 5-FU, and 30 mg/m(2) cisplatin on days 1-3 every 28 days. All courses were given on an outpatient basis. A total of 169 courses of treatment were given. In all, 18 of the 46 patients (39%) had an objective response [95% confidence interval (CI), 25%-54%] and 2 (4%) patients experienced a clinical complete response. The median duration of response was 5 months. The main side effects were hematological and gastrointestinal. Grade 3-4 toxicity was encountered as follows: leukopenia, in 9.5% of the courses; anemia, in 3%; thrombocytopenia, in 3%; nausea/vomiting, in 4%; and diarrhea, in 5%. Hospitalization due to fever and granulocytopenia was required in 5 patients, 3 of whom died of sepsis. In conclusion, FLEP shows moderate activity in patients with advanced gastric carcinoma, albeit at the cost of a high degree of toxicity. For this reason we do not recommend its use.
引用
收藏
页码:255 / 258
页数:4
相关论文
共 50 条
  • [21] CISPLATIN IN PATIENTS WITH GASTRIC-CANCER - A CANCER AND LEUKEMIA GROUP-B PHASE-II STUDY
    PERRY, MC
    GREEN, MR
    MICK, R
    SCHEIN, P
    CANCER TREATMENT REPORTS, 1986, 70 (03): : 415 - 416
  • [22] COMBINATION CHEMOTHERAPY WITH CISPLATIN AND 5-FLUOROURACIL 5-DAY INFUSION IN THE THERAPY OF ADVANCED GASTRIC-CANCER - A PHASE-II TRIAL
    LACAVE, AJ
    BARON, FJ
    ANTON, LM
    ESTRADA, E
    DESANDE, LMG
    PALACIO, I
    ESTEBAN, E
    GRACIA, JM
    BUESA, JM
    FERNANDEZ, OA
    BARON, MG
    ANNALS OF ONCOLOGY, 1991, 2 (10) : 751 - 754
  • [23] MITOMYCIN-C, ADRIAMYCIN, 5-FLUOROURACIL AND LEUCOVORIN (L-FAM2) IN THE TREATMENT OF ADVANCED GASTRIC-CANCER - A PHASE-II STUDY
    ZANIBONI, A
    SIMONCINI, E
    MARPICATI, P
    MERIGGI, F
    ARCANGELI, G
    GARATTINI, P
    RAFFAGLIO, E
    FERRAGNI, A
    MARINI, G
    TUMORI, 1991, 77 (02) : 160 - 163
  • [24] A PHASE-II STUDY OF COMBINATION THERAPY WITH 5'-DEOXY-5-FLUOROURIDINE AND CISPLATIN IN THE TREATMENT OF ADVANCED GASTRIC-CANCER WITH PRIMARY FOCI
    KOIZUMI, W
    KURIHARA, M
    SASAI, T
    YOSHIDA, S
    MORISE, K
    IMAMURA, A
    AKAZAWA, S
    BETSUYAKU, T
    OHKUBO, S
    TAKAHASHI, H
    AKIYA, T
    HAMADA, T
    KIYOHASHI, A
    CANCER, 1993, 72 (03) : 658 - 662
  • [25] PHASE-II STUDY OF 5-FLUOROURACIL AND FOLINIC ACID IN THE TREATMENT OF PATIENTS WITH ADVANCED GASTRIC-CANCER - A SOUTHWEST-ONCOLOGY-GROUP STUDY
    BERENBERG, JL
    TANGEN, C
    MACDONALD, JS
    HUTCHINS, LF
    NATALE, RB
    OISHI, N
    GUY, JT
    FLEMING, TR
    CANCER, 1995, 76 (05) : 715 - 719
  • [26] ETOPOSIDE, LEUCOVORIN, 5-FLUOROURACIL (ELF) COMBINATION CHEMOTHERAPY FOR ADVANCED GASTRIC-CANCER - EXPERIENCE WITH 2 TREATMENT SCHEDULES INCORPORATING INTRAVENOUS OR ORAL ETOPOSIDE
    TAAL, BG
    TELLER, FGM
    HUININK, WWT
    BOOT, H
    BEIJNEN, JH
    DUBBELMAN, R
    ANNALS OF ONCOLOGY, 1994, 5 (01) : 90 - 92
  • [27] Phase II study of the modified regimen of etoposide, leucovorin and 5-fluorouracil for patients with advanced gastric cancer
    Chiou, TJ
    Tung, SL
    Hsieh, RK
    Wang, WS
    Yen, CC
    Fan, FS
    Liu, JH
    Chen, PM
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1998, 28 (05) : 318 - 322
  • [28] ALTERNATING CHEMOTHERAPY IN ADVANCED GASTRIC-CANCER - A PHASE-II STUDY
    FELIU, J
    GIRON, CG
    GONZALEZBARON, M
    BERROCAL, A
    BARONSAURA, JM
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1991, 28 (04) : 313 - 314
  • [29] PHASE-II STUDY IN ADVANCED STOMACH-CANCER WITH LEUCOVORIN, ETOPOSIDE AND FLUOROURACIL IN ELDERLY PATIENTS AND IN PATIENTS WITH CARDIAC RISKS
    PREUSSER, P
    WILKE, H
    FINK, U
    ACHTERRATH, W
    LENAZ, L
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1988, 29 : 200 - 200
  • [30] 5-FLUOROURACIL, FOLINIC ACID, EPIDOXORUBICIN AND CISPLATIN (FLEP) COMBINATION CHEMOTHERAPY IN ADVANCED MEASURABLE GASTRIC-CANCER - A PHASE-II TRIAL OF THE SPANISH COOPERATIVE GROUP FOR GASTROINTESTINAL TUMOR-THERAPY (TTD)
    CERVANTES, A
    VILLARGRIMALT, A
    ABAD, A
    ANTONTORRES, A
    BELON, J
    DORTA, J
    TRES, A
    CAMPS, C
    FONSECA, E
    MASSUTI, B
    ARANDA, E
    BLANCO, E
    DEPAREDES, MG
    HERNANDEZ, JJS
    GARCIACONDE, J
    DIAZRUBIO, E
    ANNALS OF ONCOLOGY, 1993, 4 (09) : 753 - 757